Bipolar Disorder

The Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) for treatment-resistant major depressive disorder has now demonstrated promise for reducing depressive symptoms of bipolar I disorder in an open-label feasibility and safety trial.

Adherence, switching, and quality of life are top concerns in BDI, and schizophrenia.

Vanda Pharmaceuticals has submitted an NDA for approval of Bysanti for the treatment of acute bipolar I disorder and schizophrenia.

Although diagnostic criteria for a depressive episode are the same for unipolar major depression and bipolar depression, these episodes differ in their natural history.

Pipeline drug BHV-7000 failed to meet primary endpoint in a pivotal phase 2/3 trial for bipolar disorder; meanwhile, BHV-1300 sees success in sustained Reductions in Total IgG.

How should clinicians approach treatment when their patient disagrees with the diagnosis?

The FDA has accepted the supplemental New Drug Application for Uzedy extended-release injectable suspension for the maintenance treatment of bipolar I disorder in adults.

Learn more about the latest research on bipolar disorder, including the impacts of childhood trauma on its development and the correlation between bipolar disorder and cardiovascular risk.

Bipolar disorder is both underdiagnosed and overdiagnosed—though missing the diagnosis is more common. Check out this update from David N. Osser, MD.

Researchers identified 298 genetic regions linked to bipolar disorder risk in the largest study of its kind.

Bipolar I disorder (BD-I) can be difficult to diagnose and treat due to overlapping symptoms and stigma. What can clinicians utilize to help manage BD-I for better long-term outcomes?

In this CME article, learn more about recent developments with lithium as they relate to renal issues.

Looking to buy books as gifts this year? We've got you covered.

Let’s compare treatment risks when managing mixed states.

Can "healing" life trauma help improve bipolar disorder symptoms?

Here are 4 means of coping with the diagnostic uncertainty of bipolar mixed states.

How can you distinguish bipolar mixed states? Stay tuned in this short series.

Learn more about a specific subset of mood disorders.

A refined rTMS protocol, the Stanford Accelerated Intelligent Neuromodulation Therapy for major depressive disorder, shows promise in bipolar disorder.

“Older medications” like ECT, lithium, second generation antipsychotics such as the olanzapine/fluoxetine combination, have proven efficacy.

As a treatment, low-dose lithium can act like a bridge between medications and integrative approaches, supporting well-being with reduced adverse effects.

The context and timing of symptoms is critical for a timely and accurate bipolar diagnosis.

Antidepressants posed "negligible" risk of inducing mania in bipolar depression, in a target trial emulation with a larger cohort than in RCTs that have assessed this effect.

A poster presented at the 2024 ASCP Annual Meeting discussed the results of a study analyzing the treatment’s safety and efficacy in this patient population.

An expert discusses the potential of smartphones as treatment measurement tools at the 2024 ASCP Annual Meeting.

An expert discusses the role of cognition in bipolar disorder and the potential of modafinil as a treatment for it at the 2024 ASCP Annual Meeting.

An expert shares some lessons learned from prior research on the treatment and suggestions for a way forward at the 2024 ASCP Annual Meeting.

How can we enhance our lithium research?

An expert shares some clinical pearls from his lecture at the recent American Psychiatric Association Annual Meeting.

Here are highlights from the week in Psychiatric Times.